Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of
cancer-related death. Early detection of prostate cancer is largely determined by a widely …

Early detection of prostate cancer (PC) is largely carried out using assessment of prostate-
specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies …

Prostate specific antigen (PSA) remains the most used biomarker in the management of
early prostate cancer (PCa), in spite of the problems related to false positive results and …

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in
prostatic tumors. However, its clinical value has not been characterized. The aim of this …

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen
levels for the past 25 years, but with the most recent US Preventive Services Task Force …

For an efficient photoelectrocatalysis on bismuth oxychloride (BiOCl), it is highly desired to
enhance the photogenerated charge separation and the photochemical stability. Herein …

Context Prostate cancer stratification is based on tumour size, pretreatment PSA level, and
Gleason score, but it remains imperfect. Current research focuses on the discovery and …

Background There is no single definitive test to identify prostate cancer in men. Biopsies are
commonly used to obtain samples of prostate tissue for histopathological examination …

Background: Widespread use of prostate specific antigen (PSA) in screening procedures
allowed early identification of an increasing number of prostate cancers (PCas), mainly …